Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
about
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisOpening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular riskNonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB CouncilA Comparative Overview of Prescription Omega-3 Fatty Acid ProductsThe nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.PREVENTION OF ATHEROSCLEROSIS WITH LDL-C LOWERING - LIPOPROTEIN CHANGES AND INTERACTIONS: THE SANDS STUDYEffects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.Triglycerides and cardiovascular risk.Is High Serum LDL/HDL Cholesterol Ratio an Emerging Risk Factor for Sudden Cardiac Death? Findings from the KIHD Study.Using apolipoprotein B to manage dyslipidemic patients: time for a change?To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease.Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementBarriers to non-HDL cholesterol goal attainment by providers.Usefulness of apolipoprotein B/apolipoprotein A-I ratio to predict coronary artery disease independent of the metabolic syndrome in African Americans.Combination therapy of statins and fibrates in the management of cardiovascular risk.Comparison of apolipoprotein (apoB/apoA-I) and lipoprotein (total cholesterol/HDL) ratio determinants. Focus on obesity, diet and alcohol intakeCombination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapyPositive relationship between serum low-density lipoprotein cholesterol levels and visceral fat in a Chinese nondiabetic population.An equation to estimate the concentration of serum apolipoprotein B.Contemporary management and attainment of cholesterol targets for patients with dyslipidemia in China.Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges.The correlation between serum lipid profile with carotid intima-media thickness and plaque.Consensus statement on management of dyslipidemia in Indian subjects.Relationship between serum levels of fetuin-A with apo-A1, apo-B100, body composition and insulin resistance in patients with type 2 diabetesAssociation of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant.LDL-C/HDL-C Ratio Predicts Carotid Intima-Media Thickness Progression Better Than HDL-C or LDL-C Alone.Effects of age, sex, and menopausal status on blood cholesterol profile in the korean population.The role of triglycerides in atherosclerosis.Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) studyOn-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: aPatient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol: The Very Large Database oIs the ratio of apoB/apoA-1 the best predictor for the severity of coronary artery lesions in Chinese diabetics with stable angina pectoris? An assessment based on Gensini scores.Effect of the early intensive multifactorial therapy on the cardiovascular risk in patients with newly diagnosed type 2 diabetes: an observational, prospective study.Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures.Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study.The apoB100/apoAI ratio is independently associated with the severity of coronary heart disease: a cross sectional study in patients undergoing coronary angiography.Dyslipidemia in the Arabian Gulf and its Impact on Cardiovascular Risk Outcome
P2860
Q24194514-C6E3E1CD-5133-41BD-BEB5-9636C2B51FF2Q24626884-985DDB42-8B28-4D4E-86D1-AB39C8E4AAC9Q28084156-760FB8B5-9B91-422D-B5C4-260069E44A4CQ28972330-8E624660-0CF4-48EC-81D3-96BF6A38CD6AQ30357715-704B5507-F939-4142-950C-B8E6B1C0005FQ30585937-7D97282A-877F-4E16-B312-76495A1AF5B6Q33588399-32ADB86E-1F63-4263-B1B6-B3B9BEF2675FQ33620368-F5291BB0-FB73-4F24-BB63-512893C66485Q33654016-02A814F8-A405-484A-BD03-0D36DF8EA89FQ33752274-F1A23329-8525-4A76-822A-DDA56F94A12BQ33820011-9BDC0D46-9C85-43E5-998E-FBFB1CDBE064Q33820018-54D0ECEB-15E6-42EE-A615-2204F18446CFQ33972551-22565EA3-AC32-4E4F-A94C-0DB315642B49Q34154473-812CE536-2D0E-427E-B85A-87341D935D41Q34181381-22276D1F-E99B-498D-8932-859A23F6C3B4Q34270897-49B221A5-B8F6-4B9C-A4CE-D300A357AA54Q34288900-243501D2-A740-43ED-94AD-DA3822161D4BQ34305993-7B50507D-D1D2-4C72-AFE4-DC720A1D0AEAQ34358061-17110686-95C7-4DA7-8A00-2E929B173EAEQ34417470-61B97BEC-3297-4231-A5A7-CE2FC8C65371Q34514424-126016F6-1A79-490C-899F-4499C2A71FC0Q34532031-508F67DA-F5C8-45BA-99DD-C50B5E3554F8Q34672114-11BCA735-38DF-4D88-9871-0B61855F603FQ34736500-A56A86E5-31DB-4C53-8C74-061955B7F741Q34748214-048E5964-3344-40E0-9F9B-033E94DA159EQ34980772-0529763D-5386-492D-B680-BA0C256591EFQ34993000-DA9AFFDE-6991-4106-8B74-3B607611A0E1Q35008916-846F8265-ED46-4455-AEAF-209B0C1EB4A1Q35104699-FBD9297B-AA09-4872-9632-F39F4257DA39Q35215347-67DCF70A-ABB8-4163-BE54-5AA4D776D811Q35602424-069BFAA4-B21F-47E3-A5A1-850F74E24E6AQ35917143-AD449B13-D6D6-4E18-8B22-D1BDAF1D75A2Q35917224-B31A7B0D-03B6-4147-BF8F-C569E56D7F58Q35998273-1DE4EC5A-EBFC-4C0A-8AA7-89F87A7F8721Q36011273-C4D3D0F6-5562-4DEA-A11E-DA35FFAFDAC1Q36078054-54A77725-0E4B-4AF8-A16B-EFA825C4FA3BQ36199734-DE22DB2A-319C-4642-A2F9-616B85EB7778Q36240757-EF617B64-DA45-4BA6-AAE1-65D508530241Q36298497-FE138EBF-3526-45B5-BE19-5B5513904590Q36373684-6F14D822-D90B-4C6A-8BC4-BE49ADFC95C8
P2860
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Lipids, apolipoproteins, and t ...... events with statin treatment.
@en
Lipids, apolipoproteins, and t ...... events with statin treatment.
@nl
type
label
Lipids, apolipoproteins, and t ...... events with statin treatment.
@en
Lipids, apolipoproteins, and t ...... events with statin treatment.
@nl
prefLabel
Lipids, apolipoproteins, and t ...... events with statin treatment.
@en
Lipids, apolipoproteins, and t ...... events with statin treatment.
@nl
P2093
P1433
P1476
Lipids, apolipoproteins, and t ...... events with statin treatment.
@en
P2093
Anders G Olsson
David A Demicco
IDEAL Study Group
Ingar Holme
John C LaRosa
John J P Kastelein
Michael Gaffney
Michael Szarek
Nilo B Cater
Philip Barter
P304
P356
10.1161/CIRCULATIONAHA.107.713438
P407
P577
2008-06-02T00:00:00Z